Marijuana Benefits Cancer Patients: New Study Uncovers Improved Cognition and Reduced Pain
A groundbreaking study conducted by the University of Colorado has shed light on the unexpected benefits of marijuana for cancer patients and individuals undergoing chemotherapy. Contrary to common belief, consistent marijuana use from state-licensed dispensaries over a two-week period was found to enhance cognitive function and provide relief from pain. These surprising findings challenge preconceived notions about cannabis’s impact on cognition and offer hope for patients seeking alternative therapies. Published in the journal Exploration in Medicine, this study highlights the therapeutic potential of marijuana available in various state markets, while emphasizing the importance of understanding different product effects.
During the study, researchers observed that the 25 participants, who individually selected diverse edible cannabis products from Colorado dispensaries, reported improved cognitive clarity and experienced reduced pain associated with cancer symptoms and chemotherapy side effects. The fact that patients had the freedom to choose their own cannabis products adds significance to the study, as it reflects the reality of the current restricted research environment due to federal marijuana prohibition. This limitation necessitates patients purchasing their own cannabis and sharing their experiences with researchers, rather than scientists directly selecting and providing specific dispensary products for investigation.
The study also uncovered intriguing insights into the varying effects of different cannabis products. Notably, patients consuming edibles with higher CBD concentrations reported lower pain levels compared to those who consumed products with higher levels of THC. This revelation emphasizes the need for further research to guide patients in selecting the most suitable cannabis products for their specific needs. Currently, there is a lack of available data to inform individuals about the optimal choices for their desired outcomes.
To conduct the study, patients were required to purchase marijuana edibles from dispensaries. The researchers, equipped with a mobile laboratory van playfully named the “cannavan,” visited each participant’s home to administer physical and cognitive tests before and after cannabis consumption. The results demonstrated that two weeks of ad libitum cannabis use led to significant improvements in pain intensity, interference, sleep quality, and subjective cognitive functioning.
Interestingly, while patients experienced an initial intoxicating high that impaired cognition shortly after cannabis consumption, this acute effect gradually gave way to mental clarity over time, as observed during the two-week follow-up period. Objective measures of cognition, such as reaction time, also displayed improvement after prolonged cannabis use. These positive outcomes suggest that marijuana has the potential to enhance cognitive function and alleviate pain for cancer patients, highlighting its role as a potential adjunct therapy.
The study’s authors note that this observational study is among the first of its kind to examine the associations between legal market cannabis use for palliative purposes and subjective as well as objective outcomes among cancer patients. The early findings concerning pain intensity, sleep quality, and cognitive function are crucial for informing future comprehensive studies on this important topic. Gregory Giordano, one of the study authors, stressed the need for further research to explore the potential indirect role of cannabis in improving subjective cognitive function, particularly in the context of concerns about cancer treatment’s impact on cognition.
The interest in cannabis’s pain-relieving properties is heightened, especially amidst the ongoing opioid epidemic, which raises questions about the long-term risks of opioid use. Numerous studies have shown that cannabis legalization and self-reported marijuana use are associated with reduced opioid prescriptions and overdose deaths. Recent research published by the American Medical Association (AMA) supports these findings, revealing that chronic pain patients who received medical cannabis for more than a month experienced significant reductions in prescribed opioids. Another study published by the AMA last year linked state cannabis legalization to decreased opioid prescribing for specific cancer patients. Additionally, leveraging data from the federal Drug Enforcement Administration (DEA), a recent study found noteworthy reductions in the prescribing of the specific opioid codeine in states with legalized marijuana.
The groundbreaking study conducted by the University of Colorado provides valuable insights into the therapeutic potential of marijuana for cancer patients and those undergoing chemotherapy. By uncovering the benefits of marijuana in terms of improved cognition and reduced pain, this research challenges conventional beliefs and highlights the need for further exploration. With state-level marijuana legalization gaining traction, it is crucial to understand the diverse effects of different cannabis products and guide patients in making informed choices to optimize their outcomes. As the scientific community continues to push for expanded research opportunities, the potential of marijuana as a supportive treatment for cancer patients becomes increasingly promising.
